A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin

• Tarik Asselah ,

  * E-mail: tarik.asselah@bjn.aphp.fr

  Affiliation Centre de Recherche sur l’Inflammation (CRI), UMR 1149 Inserm, Université Paris Diderot, Service d’Hépatologie, AP-HP Hôpital Beaujon, Paris, France

  ⨯
• Alex J. Thompson,

  Affiliation Department of Gastroenterology, St Vincent’s Hospital, University of Melbourne, Melbourne, VIC, Australia

  ⨯
• Robert Flisiak,

  Affiliation Department of Infectious Diseases and Hepatology, Medical University of Białystok, 15–540, Białystok, Poland

  ⨯
• Manuel Romero-Gomez,

  Affiliation UCM Digestive Diseases and CIBERehd, Valme University Hospital, University of Seville, Seville, Spain

  ⨯
• Diethelm Messinger,

  Affiliation Biostatistics, PROMETRIS GmbH, 68219, Mannheim, Germany

  ⨯
• Georgios Bakalos,

  Affiliation Global Product Development Medical Affairs, F. Hoffmann-La Roche Ltd, 4074, Basel, Switzerland

  ⨯
• Mitchell L. Shiffman

  Affiliation Liver Institute of Virginia, Bon Secours Health System, Richmond and Newport News, Richmond, VA, United States of America

  ⨯